Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 999
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Alexander Zehnder M.B.A., M.D. | CEO, MD & Member of Management Board | 978,33k | N/A | 1970 |
Mr. Pierre Kemula B.Sc. | MD, CFO & Member of Management Board | 654,17k | N/A | 1975 |
Dr. Malte Greune Ph.D. | COO, Member of Management Board & MD | 600,74k | N/A | 1965 |
Dr. Myriam Mendila M.D. | Chief Development Officer, MD & Member of the Management Board | 614,49k | N/A | 1966 |
Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior VP & Area Head of Oncology | 284,14k | N/A | 1973 |
Dr. Sarah Fakih | Vice President Corporate Communications & Investor Relations | N/A | N/A | N/A |
Mr. Marco Rau L.L.M., Ph.D. | General Counsel | N/A | N/A | N/A |
Mr. Thorsten Schuller | Head of Corporate Communications | N/A | N/A | N/A |
Slavica Stevanovic-Heck | Head of Human Resources | N/A | N/A | N/A |
Dr. Patrick Baumhof | Senior Vice President of Technology | N/A | N/A | N/A |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
CureVac N.V.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.